XRCC1 and lung carcinoma: Published data have indicated that the XRCC1 genetic polymorphisms might be associated with the clinical outcome of platinum-based chemotherapy treatment in lung cancer patients7, 10, 34, 37, 43, 45, 54, 59, 60, 63, 64, 69, 71, 75, 76, 87.